Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by DAVID SANGHYUN HONG and FILIP JANKU.
DAVID SANGHYUN HONG
Connection Strength
10.259
FILIP JANKU
  1. Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precis Oncol. 2022 07; 6:e2100512.
    View in: PubMed
    Score: 0.221
  2. Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol. 2022 07; 6:e2100547.
    View in: PubMed
    Score: 0.221
  3. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist. 2021 07; 26(7):588-596.
    View in: PubMed
    Score: 0.203
  4. Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer. 2021 02 01; 127(3):391-402.
    View in: PubMed
    Score: 0.197
  5. Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. Clin Cancer Res. 2021 03 01; 27(5):1247-1255.
    View in: PubMed
    Score: 0.196
  6. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 11 01; 26(21):5579-5587.
    View in: PubMed
    Score: 0.196
  7. Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. Clin Cancer Res. 2021 01 01; 27(1):96-106.
    View in: PubMed
    Score: 0.196
  8. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 03 15; 26(6):1237-1246.
    View in: PubMed
    Score: 0.185
  9. Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2019 Apr 15; 25(8):2403-2413.
    View in: PubMed
    Score: 0.172
  10. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget. 2018 Sep 04; 9(69):33232-33243.
    View in: PubMed
    Score: 0.169
  11. Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemother Pharmacol. 2018 09; 82(3):419.
    View in: PubMed
    Score: 0.169
  12. A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemother Pharmacol. 2018 09; 82(3):407-418.
    View in: PubMed
    Score: 0.167
  13. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424.
    View in: PubMed
    Score: 0.165
  14. Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Mol Cancer Ther. 2018 03; 17(3):671-676.
    View in: PubMed
    Score: 0.161
  15. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 06; 36(3):416-423.
    View in: PubMed
    Score: 0.159
  16. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Aug 01; 23(15):4155-4162.
    View in: PubMed
    Score: 0.157
  17. Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience. 2017 May; 4(5-6):47-56.
    View in: PubMed
    Score: 0.156
  18. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656.
    View in: PubMed
    Score: 0.155
  19. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35.
    View in: PubMed
    Score: 0.154
  20. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448.
    View in: PubMed
    Score: 0.149
  21. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531.
    View in: PubMed
    Score: 0.148
  22. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016 12; 6(12):1352-1365.
    View in: PubMed
    Score: 0.148
  23. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 2016 Nov 15; 122(21):3401-3409.
    View in: PubMed
    Score: 0.146
  24. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 06; 15(6):1397-404.
    View in: PubMed
    Score: 0.144
  25. Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. J Clin Oncol. 2016 05 20; 34(15):1764-71.
    View in: PubMed
    Score: 0.143
  26. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94.
    View in: PubMed
    Score: 0.138
  27. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 Sep 15; 6(27):24581.
    View in: PubMed
    Score: 0.138
  28. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30; 6(21):18693-706.
    View in: PubMed
    Score: 0.137
  29. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21.
    View in: PubMed
    Score: 0.135
  30. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs. 2015 Jun; 33(3):621-31.
    View in: PubMed
    Score: 0.133
  31. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45.
    View in: PubMed
    Score: 0.129
  32. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res. 2014 Dec 01; 20(23):5956-63.
    View in: PubMed
    Score: 0.129
  33. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer. 2014 Dec; 14(6):468-74.
    View in: PubMed
    Score: 0.127
  34. MABp1, a first-in-class true human antibody targeting interleukin-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014 May; 15(6):656-66.
    View in: PubMed
    Score: 0.125
  35. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45.
    View in: PubMed
    Score: 0.125
  36. STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist. 2014 May; 19(5):536-44.
    View in: PubMed
    Score: 0.125
  37. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One. 2014; 9(2):e89388.
    View in: PubMed
    Score: 0.124
  38. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87.
    View in: PubMed
    Score: 0.123
  39. A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma. Oncotarget. 2014 Jan 15; 5(1):95-102.
    View in: PubMed
    Score: 0.123
  40. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol. 2013 Sep; 8(3):183-188.
    View in: PubMed
    Score: 0.115
  41. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75.
    View in: PubMed
    Score: 0.114
  42. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 01; 73(1):276-84.
    View in: PubMed
    Score: 0.113
  43. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82.
    View in: PubMed
    Score: 0.107
  44. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6(7):e22769.
    View in: PubMed
    Score: 0.103
  45. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 2011 May 17; 8(9):528-39.
    View in: PubMed
    Score: 0.102
  46. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist. 2011; 16(3):327-35.
    View in: PubMed
    Score: 0.100
  47. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011 Mar; 10(3):558-65.
    View in: PubMed
    Score: 0.100
  48. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
    View in: PubMed
    Score: 0.062
  49. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol. 2023 Feb 18; 7(1):19.
    View in: PubMed
    Score: 0.058
  50. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol. 2022 Oct 27; 6(1):78.
    View in: PubMed
    Score: 0.056
  51. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep. 2022 08 23; 12(1):14367.
    View in: PubMed
    Score: 0.056
  52. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep. 2022 05 24; 12(1):8701.
    View in: PubMed
    Score: 0.055
  53. Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study. Invest New Drugs. 2022 Apr; 40(2):463.
    View in: PubMed
    Score: 0.054
  54. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Exp Hematol Oncol. 2021 Dec 29; 10(1):59.
    View in: PubMed
    Score: 0.053
  55. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Invest New Drugs. 2022 04; 40(2):290-299.
    View in: PubMed
    Score: 0.052
  56. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer. 2022 02; 20(1):e16-e24.
    View in: PubMed
    Score: 0.052
  57. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther. 2021; 14:3037-3049.
    View in: PubMed
    Score: 0.051
  58. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol. 2021 Mar 19; 5(1):21.
    View in: PubMed
    Score: 0.050
  59. Associations between the gut microbiome and fatigue in cancer patients. Sci Rep. 2021 03 12; 11(1):5847.
    View in: PubMed
    Score: 0.050
  60. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer. 2021 04; 124(9):1533-1539.
    View in: PubMed
    Score: 0.050
  61. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.049
  62. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol. 2020; 9:7.
    View in: PubMed
    Score: 0.047
  63. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
    View in: PubMed
    Score: 0.047
  64. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080.
    View in: PubMed
    Score: 0.047
  65. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 12 30; 12(1):145.
    View in: PubMed
    Score: 0.046
  66. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
    View in: PubMed
    Score: 0.046
  67. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer. 2019 Oct; 136:158.
    View in: PubMed
    Score: 0.045
  68. Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precis Oncol. 2018; 2.
    View in: PubMed
    Score: 0.042
  69. Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget. 2018 Sep 07; 9(70):33258-33270.
    View in: PubMed
    Score: 0.042
  70. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol. 2018 11; 82(5):877-885.
    View in: PubMed
    Score: 0.042
  71. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309.
    View in: PubMed
    Score: 0.042
  72. Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. J Comput Assist Tomogr. 2018 May/Jun; 42(3):357-364.
    View in: PubMed
    Score: 0.041
  73. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. 2018 07; 17(7):1595-1601.
    View in: PubMed
    Score: 0.041
  74. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018 06; 120:137-141.
    View in: PubMed
    Score: 0.041
  75. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer. 2018 03 20; 118(6):763-769.
    View in: PubMed
    Score: 0.041
  76. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017 12 19; 5(1):100.
    View in: PubMed
    Score: 0.040
  77. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646.
    View in: PubMed
    Score: 0.040
  78. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017 11 21; 7(1):15963.
    View in: PubMed
    Score: 0.040
  79. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188.
    View in: PubMed
    Score: 0.040
  80. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017.
    View in: PubMed
    Score: 0.040
  81. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173.
    View in: PubMed
    Score: 0.039
  82. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017 Jun 13; 8(24):39254-39267.
    View in: PubMed
    Score: 0.039
  83. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
    View in: PubMed
    Score: 0.039
  84. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8).
    View in: PubMed
    Score: 0.038
  85. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.
    View in: PubMed
    Score: 0.038
  86. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444.
    View in: PubMed
    Score: 0.037
  87. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology. 2017; 92(1):14-20.
    View in: PubMed
    Score: 0.037
  88. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 10; 15(10):2475-2485.
    View in: PubMed
    Score: 0.037
  89. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 2016 07; 78(1):167-71.
    View in: PubMed
    Score: 0.036
  90. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43.
    View in: PubMed
    Score: 0.036
  91. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res. 2016 07 01; 76(13):3690-701.
    View in: PubMed
    Score: 0.036
  92. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 05; 77(5):1097-102.
    View in: PubMed
    Score: 0.036
  93. Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Apr; 77(4):881.
    View in: PubMed
    Score: 0.036
  94. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol. 2016 05; 77(5):973-7.
    View in: PubMed
    Score: 0.036
  95. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Feb; 77(2):357-64.
    View in: PubMed
    Score: 0.035
  96. Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. Gynecol Oncol Res Pract. 2015; 2:10.
    View in: PubMed
    Score: 0.035
  97. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62.
    View in: PubMed
    Score: 0.035
  98. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.
    View in: PubMed
    Score: 0.034
  99. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62.
    View in: PubMed
    Score: 0.034
  100. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs. 2015 Aug; 33(4):911-20.
    View in: PubMed
    Score: 0.034
  101. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015 Jun; 33(3):700-9.
    View in: PubMed
    Score: 0.034
  102. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer. 2015 Sep; 23(9):2649-54.
    View in: PubMed
    Score: 0.033
  103. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014; 9(12):e115383.
    View in: PubMed
    Score: 0.033
  104. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79.
    View in: PubMed
    Score: 0.033
  105. Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 2014 Nov 15; 5(21):10280-92.
    View in: PubMed
    Score: 0.033
  106. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33(1):215-24.
    View in: PubMed
    Score: 0.032
  107. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs. 2015 Feb; 33(1):177-86.
    View in: PubMed
    Score: 0.032
  108. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46.
    View in: PubMed
    Score: 0.032
  109. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84.
    View in: PubMed
    Score: 0.032
  110. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 2014; 1(8):540-9.
    View in: PubMed
    Score: 0.032
  111. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. Oncoscience. 2014 Jul 27; 1(7):522-530.
    View in: PubMed
    Score: 0.032
  112. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26.
    View in: PubMed
    Score: 0.032
  113. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014 Sep 15; 20(18):4827-36.
    View in: PubMed
    Score: 0.032
  114. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9.
    View in: PubMed
    Score: 0.032
  115. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget. 2014 May 30; 5(10):3029-38.
    View in: PubMed
    Score: 0.031
  116. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res. 2014 May; 34(5):2349-55.
    View in: PubMed
    Score: 0.031
  117. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw. 2014 Feb; 12(2):194-203.
    View in: PubMed
    Score: 0.031
  118. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014 Mar; 73(3):495-501.
    View in: PubMed
    Score: 0.031
  119. Retreatment after secondary resistance or mixed response: a pilot study. Oncology. 2013; 85(6):350-5.
    View in: PubMed
    Score: 0.030
  120. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs. 2014 Jun; 32(3):465-72.
    View in: PubMed
    Score: 0.030
  121. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist. 2013; 18(12):1315-20.
    View in: PubMed
    Score: 0.030
  122. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63.
    View in: PubMed
    Score: 0.030
  123. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs. 2014 Apr; 32(2):279-86.
    View in: PubMed
    Score: 0.029
  124. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget. 2013 Jun; 4(6):890-8.
    View in: PubMed
    Score: 0.029
  125. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget. 2013 May; 4(5):772-84.
    View in: PubMed
    Score: 0.029
  126. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013 May; 4(5):705-14.
    View in: PubMed
    Score: 0.029
  127. Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol. 2013 Mar 20; 31(9):e137-40.
    View in: PubMed
    Score: 0.029
  128. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65.
    View in: PubMed
    Score: 0.029
  129. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83.
    View in: PubMed
    Score: 0.028
  130. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One. 2012; 7(5):e38033.
    View in: PubMed
    Score: 0.027
  131. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One. 2011; 6(10):e25806.
    View in: PubMed
    Score: 0.026
  132. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 Nov 01; 17(21):6840-6.
    View in: PubMed
    Score: 0.026
  133. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 2012 Mar 01; 118(5):1422-8.
    View in: PubMed
    Score: 0.026
  134. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res. 2010 Aug 01; 16(15):4031-7.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.